FDA Approves Leucovorin Only For Rare Folate Transport Disorder
FDA approved Wellcovorin for cerebral folate deficiency (FOLR1 variant) but said evidence doesn't support broad use for autism; outpatient prescriptions rose 71% after September promotion.
Daily BeastRFK Jr. Humiliated as His Own Agency Calls Out Autism Lies
ARS TechnicaFDA contradicts Trump admin, declines to approve generic drug for autism
GizmodoBait and Switch? RFK Jr.'s FDA Pivots on 'Promising' Autism Treatment Leucovorin
World News GroupFDA OKs leucovorin to treat rare disorder, not most autism
Overview
The FDA approved leucovorin (Wellcovorin) for adults and children with cerebral folate deficiency linked to a FOLR1 gene variant and did not approve it for autism, the agency said.
The action follows a September White House event where HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary touted leucovorin as potentially helpful for children with autism.
Senior FDA officials said their review focused on the strongest evidence, found insufficient support for broad autism use, and noted a supporting study was retracted in January.
Researchers found outpatient leucovorin prescriptions for children ages 5 to 17 rose 71 percent in the three months after the late September news conference.
The FDA said it is allowing imports of the drug to help boost supply.
Analysis
Center-leaning sources present an evidence-focused, corrective account: they attribute optimistic claims to Trump and administration officials, report FDA’s narrowed findings and a retracted study, include expert cautions and family impacts, and avoid loaded editorial language. Source content (quotes, studies) is clearly attributed, limiting editorial framing.
FAQ
Cerebral folate deficiency caused by FOLR1 variants is a rare genetic disorder resulting from loss of function of the folate receptor alpha (FOLR1) protein, which prevents adequate folate transport to the brain despite normal systemic folate levels[2]. Untreated patients experience progressive neurologic deterioration including developmental delays, cognitive impairment, seizures, movement disorders such as ataxia and tremors, intellectual disability, and speech difficulties[2][8]. Some patients may progress to immobility if left untreated[2].
Leucovorin treatment is highly effective for FOLR1-CFTD when initiated early[1][2]. **High-dose 5-formyltetrahydrofolate (folinic acid) can result in substantial improvement in neurologic findings**, particularly when started at a young age, with improvements in seizure frequency, language skills, walking ability, and cognitive function[1][2]. Early treatment can prevent irreversible cognitive deficits and may even lead to significant or complete regression of neurological symptoms[1]. The earlier treatment is administered, the better the response[1].
The FDA determined there is **insufficient evidence supporting broad use of leucovorin for autism**[2][4]. Senior FDA officials stated their review focused on the strongest available evidence and found it did not support autism treatment[2]. Additionally, a supporting study was retracted in January, further weakening the case for autism use[2]. While some research has explored potential connections, the scientific evidence does not meet FDA approval standards for this broader indication.
Treatment with folinic acid should be initiated slowly over the first month using half the final required dose[5]. Abrupt dose increases can cause elevated production of neurotransmitters (dopamine and serotonin), leading to overstimulation and symptoms such as marked agitation and aggression[5]. It typically takes about 6 weeks to establish a new equilibrium between augmented neurotransmitter production and dopamine and serotonin receptors[5]. Additionally, supplementation with folic acid (rather than folinic acid) is not recommended as it is associated with adverse effects including seizures[6].
Yes, treatment of asymptomatic or mildly symptomatic younger siblings at the time of diagnosis of their older siblings can **prevent or markedly mitigate the neurocognitive signs** of FOLR1-CFTD[2]. Early prophylactic treatment in younger relatives who carry the same genetic variant may prevent neurological signs from developing altogether and lead to significant symptom regression[1].
